On Tuesday, markets fluctuated before moving higher as Fed Chairman Jerome Powell testified before Congress. Powell told lawmakers that the tax reform bill signed into law last year will provide "meaningful support (for the GDP) for the next two to three years." Powell advocated for open trade agreements, asserting that countries that are open to trade tend to do better historically.

Netflix (NFLX - Get Report)  shares fell but cut its losses after missing estimates on subscriber growth.

Shares of Amazon (AMZN - Get Report) gained after its 36-hour Prime Day event initialy began with website issues.

Goldman Sachs Group (GS - Get Report)  reported second-quarter profit, and named company President David Solomon to succeed Lloyd Blankfein as CEO, effective Oct. 1.

(Goldman Sachs and Amazon are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells GS or AMZN? Learn more now.)

Here are three top takes from the columnists of Real Money and Real Money Pro, our premium sites for Wall Street professionals and active investors:

Jim Cramer: A Pretty Wild Rally In Three Oppositional Groups

"You combine a Fed Chairman who doesn't want to throw us into a recession, which has suddenly become a big worry, with the absence of negative trade news and you get a pretty wild rally in not two but three oppositional groups, something that's not supposed to be happening and historically almost never does, "says TheStreet's Jim Cramer.

"How can this be? Let's take a look at the camps so we can figure it out," Cramer adds. 

How to Play Goldman Sachs After Its Big Earnings Beat

Real Money columnist James DePorre notes: "Positive responses to bank earnings on Monday helped to offset broad weakness. Tuesday morning Goldman Sachs (GS - Get Report)  reported its results and the big question is whether it can keep the momentum going in the financial sector. Banks and financials have been the laggard group for a while, but bargain hunters have discovered them and are accumulating as valuations look reasonable compared to other areas of the market."

BioMarin Paces a Very Strong Biotech Group

"With much of the chatter over reduced drug pricing this year at the persuasion of President Trump, we saw this group get pounded with some heavy selling in the early part of 2018. Yet, once the very strong rhetoric died down, buyers started to come back, and over the past few months these are some of the best charts out there," writes  Real Money Pro columnist Robert Lang.